iScience-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2022-12-24 马疾香幽来自上海

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：癌症生物学;肿瘤
经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。

83 32

展开32条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2022-08-08 1250d11bm60(暂无昵称)

目前即使IF=3.3

69 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2021-11-01 王0000

最近审稿是变慢了吗 with editor
已经半个月了

106 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2023-06-30 ms1000000536422640 来自江苏省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：炎症;药物;神经内科
经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up

59 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2022-11-16 ms3000001098037581

偏重的研究方向：癌症生物学
经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。

71 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2024-03-12 ms2000000185262432 来自广西

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing

25 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2023-06-30 山蛙来自湖北省

谁能告诉我这还是当初好多人说的潜力股吗？

45 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2023-03-19 ms5000002030983398

有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂

64 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2024-03-26 易挥发来自广东省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：外泌体;肿瘤标志物
经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。

14 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：癌症生物学;肿瘤 经验分享：投稿时间节点：文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1237325, encodeId=df09123e32514, content=目前即使IF=3.3, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Mon Aug 08 13:06:08 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065952, encodeId=3b9c1065952ce, content=最近审稿是变慢了吗 with editor 已经半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4e92495496, createdName=王0000, createdTime=Mon Nov 01 20:26:18 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;药物;神经内科 经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2100981, encodeId=71b9210098187, content=偏重的研究方向：癌症生物学 经验分享：二审返回去一个月了，all reviews complete 10天了，还没改状态，慌的一批。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=ms3000001098037581, createdTime=Wed Nov 16 22:14:25 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2120383, encodeId=b5ae2120383dd, content=有没有朋友类似情况：已经原则上接受，可编辑每次返回来一个格式小问题要改，一次又不说完，每次一点小问题，要被逼崩溃了😂😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be95700047, createdName=ms5000002030983398, createdTime=Sun Mar 19 09:15:05 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省)]

2023-02-10 1250d11bm60(暂无昵称) 来自浙江省

的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE，审稿人很专业。

61 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务